Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars-Reference-Cited by-同舟云学术

Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars

Published:2020-09-04 Issue:1 Volume:21 Page:75-80
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Prignano Francesca¹,Choi Jaeyun²,Pieper Burkhard³,Iversen Lars⁴

Affiliation:

1. Department of Health Sciences, Dermatology Unit, University of Florence, Florence, Italy

2. Medical Affairs, Samsung Bioepis Co., Ltd., Incheon, Republic of Korea

3. Scientific Affairs Biosimilars, Biogen International GmbH, Baar, Switzerland

4. Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark

Funder

Samsung Bioepis and Biogen

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2020.1812576

Reference39 articles.

1. Vasiliou C, Huntley C, Kurniawan A. Datamonitor Healthcare. Psoriasis market and forecast analysis to 2025 [Internet]. 2018 [cited 2020 Mar 10]. Available from: https://pharmastore.informa.com/product/psoriasis/

2. Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience

3. European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC

4. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fluorescence-Based Lateral Flow Immunoassay for Quantification of Infliximab: Analytical and Clinical Performance Evaluation;Therapeutic Drug Monitoring;2024-05-15

2. Estimation of patients with psoriasis potentially eligible and currently untreated with biological drugs in Italy;Italian Journal of Dermatology and Venereology;2023-11

3. Bio‐experienced psoriasis patients treated with anti‐interleukin monoclonal antibodies are less likely to achieve PASI 90, PASI 100, PASI ≤ 1 and ≤3: Results from a cohort of 305 patients;JEADV Clinical Practice;2023-10-09

4. Biosimilars approved for psoriasis treatment in Europe;PONS - medicinski casopis;2023

5. The Rise of Anti-TNF Biosimilars: Guidelines, Real-World Evidence, and Challenges to Acceptance;EMJ Gastroenterology;2022-11-04